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Abstract
Iron transport in the plasma is carried out by transferrin, which donates iron to cells through its interaction with a specific
membrane receptor, the transferrin receptor (TfR). A soluble form of the TfR (sTfR) has been identified in animal and human
serum. Soluble TfR is a truncated monomer of tissue receptor, lacking its first 100 amino acids, which circulates in the form of a
complex of transferrin and its receptor. The erythroblasts rather than reticulocytes are the main source of serum sTfR. Serum
sTfR levels average 5.0F 1.0 mg/l in normal subjects but the various commercial assays give disparate values because of the
lack of an international standard. The most important determinant of sTfR levels appears to be marrow erythropoietic activity
which can cause variations up to 8 times below and up to 20 times above average normal values. Soluble TfR levels are
decreased in situations characterized by diminished erythropoietic activity, and are increased when erythropoiesis is stimulated
by hemolysis or ineffective erythropoiesis. Measurements of sTfR are very helpful to investigate the pathophysiology of
anemia, quantitatively evaluating the absolute rate of erythropoiesis and the adequacy of marrow proliferative capacity for any
given degree of anemia, and to monitor the erythropoietic response to various forms of therapy, in particular allowing to predict
response early when changes in hemoglobin are not yet apparent. Iron status also influences sTfR levels, which are considerably
elevated in iron deficiency anemia but remain normal in the anemia of inflammation, and thus may be of considerable help in
the differential diagnosis of microcytic anemia. This is particularly useful to identify concomitant iron deficiency in a patient
with inflammation because ferritin values are then generally normal. Elevated sTfR levels are also the characteristic feature of
functional iron deficiency, a situation defined by tissue iron deficiency despite adequate iron stores. The sTfR/ferritin ratio can
thus describe iron availability over a wide range of iron stores. With the exception of chronic lymphocytic leukemia (CLL) and
high-grade non-Hodgkin’s lymphoma and possibly hepatocellular carcinoma, sTfR levels are not increased in patients with
malignancies. We conclude that soluble TfR represents a valuable quantitative assay of marrow erythropoietic activity as well as
a marker of tissue iron deficiency.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Iron transport in the plasma is carried out by
transferrin, which donates iron to cells through its
interaction with a specific membrane receptor. The
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transferrin receptor (TfR) is a 760-amino-acid glyco-
protein. The functional receptor is composed of two
such monomers, linked by two disulfide bridges to
form a molecule of 190,000 Da. Virtually all cells,
except mature red cells, have TfR on their surface, but
the largest numbers are in the erythron, placenta and
liver. In a normal adult, about 80% of TfR are in the
erythroid marrow. Receptor density on proliferating
cells is related to the availability of iron as deprivation
of iron results in prompt induction of TfR synthesis
whereas excess iron suppresses TfR numbers. There-
fore, the total mass of cellular TfR depends both on
the number of erythroid precursors in the bone mar-
row and on the number of TfR per cell, a function of
the iron status of the cell.
A circulating form of TfR has been found in
human as well as animal serum. Serum TfR (sTfR)
is a soluble truncated monomer of tissue receptor,
lacking its first 100 amino acids, which circulates in
the form of a complex of transferrin and its receptor
[1]. A possible conformation is two receptor mono-
mers (85 kDa) binding to one transferrin molecule (80
kDa) to give a total MW of around 250 kDa. A very
small amount (although this may vary with the
patient’s diagnosis) of circulating TfR is in the form
of an intact dimer in exosomes [2]. Soluble TfR is
produced by proteolysis, mediated by a membrane-
associated serine protease that occurs mostly at the
surface of exosomes within the multivesicular body
prior to exocytosis [3]. The bulk of sTfR measured in
serum is proportional to the mass of cellular TfR [4]
and originates mostly from erythroblasts and to a
lesser extent from reticulocytes [5].
In this review, we will highlight the value of soluble
sTfR as a quantitative measure of erythropoietic activ-
ity and as a marker of tissue iron deficiency. This will
be extensively illustrated by presenting numerous
examples of the practical use of this assay in the
evaluation of erythropoiesis and/or iron status in an
individual as well as in defined populations of patients.
Potential pitfalls in the interpretation of sTfR values
will be discussed.
2. Soluble TfR in normal subjects
Kohgo et al. [6] and Beguin et al. [7] were the first to
measure sTfR quantitatively in human and rat serum,
respectively. A number of quantitative assays have
been set up to measure sTfR levels in biological fluids
such as culture supernatants and plasma or serum.
Some have been developed in research laboratories
but several are now commercially available. The per-
formance of these assays is highly variable but the
major problem is the lack of an international standard.
Therefore, although levels measured by various assays
may correlate well, direct clinical comparison of values
obtained with different assays is difficult. Using our
assay, sTfR levels averaged 5.0F 1.0 mg/l (meanF
S.D.) in a group of 165 normal human subjects and
were remarkably stable over time in the same sub-
ject. No differences are observed with sex or age in
the 18–80-year age range [8], but levels are some-
what higher in fetuses and newborns compared to
adults. In the early postnatal period, sTfR levels are
comparable to those of adults with marrow suppres-
sion, but they soon increase again so that infants
[9] and adolescents [10] tend to have slightly higher
sTfR levels than adults. Age-specific reference limits
for children aged 0–4, 4–10 and 10–16 years could
be derived in a carefully selected group of healthy
children from the observation of a continuous dec-
line of sTfR values from birth to late adolescence
[11].
3. Soluble TfR and erythropoiesis
3.1. Soluble TfR and erythropoietic activity
Erythropoietic activity has been found to be the
most important determinant of sTfR levels [6,7,
12,13]. Decreased sTfR levels are found in situations
characterized by erythroid hypoplasia (Fig. 1), such as
hypertransfusion, chronic renal failure, severe aplastic
anemia or after intensive chemotherapy [14].
Increased sTfR levels are seen in situations of stimu-
lated erythropoiesis (Fig. 2), such as congenital dys-
erythropoietic anemia, hemolytic anemia, hereditary
spherocytosis, sickle cell anemia, thalassemia major
or intermedia, megaloblastic anemia or secondary
polycythemia. Levels range from a minimum of about
0.5 mg/l—the contribution of nonerythroid tissues—
when erythropoiesis is totally absent, to about 100
mg/l in severely anemic thalassemia patients [12]. The
dependence of sTfR levels on the activity of the
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erythron is further demonstrated by the strong corre-
lation observed with ferrokinetic measurements of
erythropoiesis. This has first been shown in rats with
normal, suppressed, or stimulated erythropoiesis [7].
This has also been confirmed in humans in whom the
relationship between mean erythron transferrin uptake
(ETU) and mean sTfR level in groups of subjects with
a variety of diagnoses is very close to the line of
proportionality [12,15]. The greater precision and
simpler methodology of sTfR determination should
thus make it the method of choice to quantitate total
erythropoiesis.
3.2. Soluble TfR and pathophysiology of anemias
Erythropoietin (Epo) production is regulated
through a feedback system between the bone marrow
and the kidney through which serum Epo levels
increase exponentially in proportion to the degree of
anemia. In the presence of a normal marrow stem cell
reserve, erythropoiesis increases in proportion to Epo
stimulation and thus sTfR also rise exponentially in
response to anemia [15].
We thus constructed reference regressions repre-
senting the normal relationships between hematocrit
(Hct) on the one hand, and Epo or sTfR on the other,
based on normal subjects and patients with hemolytic
anemia [15]. Based on these formulas, predicted
log(Epo) and log(sTfR) values were derived for each
Hct, O/P ratios of observed/predicted log(Epo) or
log(sTfR) were derived, and 95% confidence limits
were obtained in order to define a range of reference
values for individual O/P ratios. These limits are
0.80–1.20 for O/P Epo and 0.90–1.10 for O/P sTfR.
The pathophysiology of anemia can therefore be
assessed by a simple determination of the patient’s
Hct, serum Epo and sTfR. These measurements are
best expressed in relation to the degree of anemia to
avoid gross overestimation of marrow proliferative
capacity. When investigating a group of patients, this
can be achieved by comparing patients and reference
subjects (hemolytic anemia) by regression analysis.
When studying an individual patient, this can be
obtained by the O/P ratio. Then not only the absolute
rate but also the adequacy of Epo production (O/P
Epo) and of marrow response to Epo stimulation (O/P
sTfR) can be evaluated as appropriate or not for a
given degree of anemia.
As shown in Table 1, three major patterns of
erythropoiesis are described on the basis of the Hct,
O/P sTfR and O/P Epo, while the retic index and sTfR
levels serve to separate major patterns into variants
[15]. Normal Hct, O/P Epo and O/P TfR define a
normal pattern of erythropoiesis. The sTfR value helps
differentiate a variant of compensated hemolysis in
which sTfR is increased. Decreased Hct and normal
O/P Epo and O/P sTfR characterize a pattern of
‘‘hyperdestruction’’. The reticulocyte index helps
break this group down into two variants of ‘‘hemo-
lysis’’ (index >3) and ‘‘ineffective erythropoiesis’’
Fig. 2. MeanF 1 S.D. sTfR levels in groups of patients with
hyperplastic erythropoiesis, including autoimmune hemolytic ane-
mia (AIHA), hereditary spherocytosis (HS), h-thalassemia major
(Thal), HbH disease (HbH), or polycythemia (PC). The gray zone
represents the reference interval in normal subjects.
Fig. 1. MeanF S.D. sTfR levels in groups of patients with
hypoplastic erythropoiesis, including severe aplastic anemia (AA),
chronic renal failure (CRF), or after intensive chemotherapy
(Chemo). The gray zone represents the reference interval in normal
subjects.
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(index < 2). The pattern of ‘‘erythroid marrow hypo-
proliferation’’ is defined by erythropoietic activity
inadequately low for the degree of anemia (decreased
O/P sTfR). This can be related to defective Epo
production (low O/P Epo) or intrinsic marrow failure
(normal O/P Epo). Marrow hypoproliferation can be
absolute (decreased sTfR), i.e. ‘‘hypoproliferative ane-
mia’’, or relative (normal/increased sTfR), termed
‘‘mixed disorder of erythropoiesis’’, i.e. with both hy-
perdestruction and hypoproliferation components. The
model is thus very useful for detecting the presence
of multiple mechanisms of anemia in the same patient,
particularly a component of hypoproliferation being
associated with hyperdestruction.
This functional classification of anemia reveals that
a same clinical diagnosis may be associated with
different patterns of erythropoiesis, while a same
pattern of erythropoiesis can be seen across different
clinical groups [15]. A typical example is the anemia
of chronic disorders. Children with acute leukemia or
solid tumors have adequate Epo production but pro-
foundly suppressed erythropoiesis [16]. Patients with
chronic lymphocytic leukemia (CLL) appear to have
appropriate Epo production and erythroid marrow
response for the degree of anemia, although erythro-
poiesis may become impaired in advanced stages [17].
A significant proportion of multiple myeloma patients
has relative marrow failure in large part due to
inadequate Epo production [18]. Defective iron sup-
ply to the erythron rather than blunted Epo production
is the major cause of anemia associated with systemic-
onset juvenile arthritis, resulting in elevated sTfR
levels that return to normal following correction of
anemia with intravenous (IV) iron [19].
3.3. Soluble TfR and erythropoietic response to treat-
ment
Serum sTfR determinations are ideal for situations
in which serial measurements of erythropoiesis are
needed, for instance, after bone marrow transplanta-
tion. It has thus been possible to demonstrate that the
development of erythropoiesis after autologous trans-
plantation is determined by the overall marrow pro-
liferative capacity and that Epo plays only a
facilitating role, while after allogeneic transplantation,
erythropoiesis depends on Epo production which
remains inadequate for prolonged periods of time
[14]. Compared to autologous bone marrow trans-
plantation, the use of peripheral blood stem cells is
associated with faster erythroid recovery and higher
Epo consumption [20]. Soluble TfR may be used to
monitor erythropoietic response to various forms of
therapy, including the treatment of pure red cell
aplasia with cyclosporine [21], of congenital Epo-
dependent erythrocytosis with theophylline [22], or
of thalassemia intermedia with butyrate [23]; the
correction of megaloblastic anemia with cobalamin
Table 1
Patterns of erythropoiesis in the investigation of the pathophysiology of anemia based on the hematocrit, the reticulocyte index, serum sTfR, O/
P (observed/predicted) sTfR and O/P Epo
Erythropoiesis
pattern
Main characteristics Hct O/P sTfR O/P Epo sTfR Retic indexa Example
Normal Normal N N N N N Normal
Compensated
hemolysis
N N N z z Hereditary
spherocytosis
Hyperdestruction Hemolysis # N N z z AIHA
Ineffective
erythropoiesis
# N N z # Thalassemia
Hypoproliferation Marrow failure # # N # # Aplastic anemia
Defective Epo
production
# # # # # Renal failure
Mixed disorder Marrow failure # # N N–z # MDS
Defective Epo
production
# # # N–z # Cancer
AIHA= autoimmune hemolytic anemia. MDS=Myelodysplastic syndrome.
a Retic index: < 2 is low, >3 is high.
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[21] or of iron deficiency anemia with iron [19]; the
removal of excess iron by phlebotomy [24]; the
response of aplastic anemia to immunosuppressive
therapy [25]; the recovery of erythropoiesis after renal
transplantation [26]; and the correction of hypersplen-
ism following splenectomy [27].
Evaluation of marrow erythropoietic activity by
sTfR is also valuable in patients receiving chronic
transfusions. In thalassemia major, the recommended
practice is to transfuse patients at a hemoglobin (Hb)
level of 9–11 g/dl to decrease iron absorption through
erythroid marrow suppression, while avoiding exces-
sive transfusion-associated iron overload. Measure-
ments of sTfR levels have demonstrated that patients
who undergo blood transfusions at regular intervals
show better marrow suppression than those who are
transfused more sporadically [28]. Nonetheless, this
policy was not adequate in a number of patients who
either were overtransfused or did not reach adequate
inhibition of ineffective erythropoiesis [29]. The assay
of sTfR may thus be useful to better individualize the
transfusion regimen. The same conclusions were
derived in patients with sickle cell anemia [30],
although similar myelosuppression with increased
fetal hemoglobin can be achieved with hydroxyurea
[31].
Soluble TfR is of particular interest in assessing
response to recombinant human erythropoietin
(rHuEpo) in patients with chronic renal failure
[32,33], aplastic anemia [34], pure red cell aplasia
[35], thalassemia intermedia [36], cancer [37–39],
myelodysplastic syndrome (MDS) [37,40], rheuma-
toid arthritis [41], genetic hemochromatosis [42] or in
intensive care [43], as well as in normal subjects [44],
autologous blood donors [45] and premature infants
[46] or after stem cell transplantation [47,48]. Sim-
ilarly, sTfR levels can be used to monitor how
erythropoiesis subside after cessation of rHuEpo
therapy [49]. Measurements of sTfR and calculated
sTfR/ferritin ratios have also been proposed as pos-
sible probes to detect erythropoietin abuse in athletes
[44], although lower rHuEpo doses inducing similar
Hct changes over a longer period of time are not
associated with sTfR changes [50]. Therefore, com-
bining sTfR measurements into a multiparametric
assessment of erythroid marrow function may
improve the detection of rHuEpo abuse [50,51].
However, intermittent or continuous hypoxia [52] as
achieved by a ‘‘living high-training low’’ program [53]
also induce endogenous Epo-driven elevated sTfR
values.
In response to rHuEpo, the erythroblast compart-
ment is very slow to respond, expanding over a period
of 6 weeks before reaching a steady state during which
the Hb continue to rise [32]. The dose of rHuEpo
needed to achieve response is highly variable because
of such interfering factors as functional iron deficiency
or inflammation. Early recognition of a low probabil-
ity of hematologic response could help identify and
correct specific causes of treatment failure or suggest
rapid dose escalation, in order to hasten clinical
improvement and avoid prolonged ineffective use of
an expensive medication. Measurement of sTfR levels
may play a major role in this area. In hemodialysis
patients, a good prediction of response was obtained
with baseline sTfR (< or z 3.5 mg/l) and fibrinogen,
illustrating the importance of subclinical inflammation
(higher fibrinogen) and functional iron deficiency
(higher sTfR) in impairing response to rHuEpo [33].
In cancer patients, inadequately low serum Epo levels
are associated with a much better chance of respond-
ing to treatment [38]. Evaluating the early erythro-
poietic response to rHuEpo before a significant change
in Hct can be observed is also very helpful. In
hemodialysis patients, a sTfR increment of at least
20% after 2 weeks secured a response in virtually
100% of the patients [33]. In cancer patients, several
studies have shown that the hematologic response to
rHuEpo was strongly associated with early increases
of sTfR levels (20–25% over baseline) after 1–2
weeks of treatment [37–39]. A combination of base-
line parameters and early changes observed after 2
weeks of rHuEpo may provide another useful
approach. This has first be proposed in hemodialysis
patients by combining baseline sTfR and fibrinogen
with the 2-week sTfR increment [33]. In cancer
patients, the combined use of baseline serum Epo
and the 2-week sTfR increment proved to be very
powerful, achieving an overall accuracy of 90% [38].
However, early prediction of response based on sTfR
elevation early in the course of treatment will not be
valid in patients in whom rHuEpo essentially stim-
ulates ineffective erythropoiesis, for instance, some
patients with MDS [37,40]. Nevertheless, failure to
increase sTfR levels still strongly predict for treatment
failure [54].
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4. Soluble TfR and iron status
4.1. Soluble TfR and iron status
The iron status also influences sTfR levels in
serum (Fig. 3) [7]. In subjects with elevated trans-
ferrin saturation [55,56], African iron overload
[57,58] or genetic hemochromatosis [12,57,59], aver-
age sTfR levels are about 20% below those measured
in normal subjects but most values are still within the
normal range. Iron deficiency has a much stronger
impact on sTfR levels [60]. Soluble TfR levels in
severely anemic iron-deficient rats increase many
folds over normal values, in proportion to the
increase documented for erythron membrane recep-
tors [7]. As compared to normal individuals, levels
are marginally increased in nonanemic iron-deficient
subjects but more dramatically so in patients with
iron deficiency anemia [12,13,61,62]. In such
patients, sTfR levels exhibit strong correlations with
various red cell indices indicative of iron deficiency
[63,64] and are inversely related to serum ferritin
[62]. The elevation of sTfR with iron deficiency has
been confirmed by the evaluation of stainable marrow
iron [65,66].
Skikne et al. [67] have published an elegant study
on the clinical utility of sTfR as a marker of the iron
status. When normal volunteers underwent graded
phlebotomy, ferritin decreased progressively while
sTfR did not change much during the phase of storage
iron depletion. However, sTfR increased significantly
when marrow functional iron deficiency and anemia
developed. Therefore, the iron status may be fully
assessed by using serum ferritin as a measure of iron
stores (storage iron depletion), sTfR as a measure of
functional tissue iron deficiency (iron-deficient eryth-
ropoiesis), and hemoglobin as a measure of advanced
iron deficiency (iron deficiency anemia). Because of
the reciprocal relationship between serum sTfR and
ferritin measurements, the ratio of sTfR/ferritin
describes a perfect log-linear relationship to body iron
over a wide range of normal and depleted iron stores
[67]. This can also be obtained by the log of the ratio
of sTfR to ferritin [68] or by the sTfR–ferritin index,
the ratio of sTfR to log ferritin [61,69]. These ratios
increase the sensitivity of sTfR in detecting latent iron
deficiency. Conversely, for the assessment of ID
anemia, the increase of sTfR usually does not exceed
the diagnostic value of a low serum ferritin [70] or
reticulocyte Hb content [71], or an elevated zinc
protoporphyrin [72]. However, the gold standard for
defining iron deficiency in these studies was very
variable and not always adequate.
Iron supplementation returns sTfR to normal val-
ues but this may be preceded by some transient
elevation, possibly reflecting expansion of the eryth-
roid marrow [73]. In 2 double-blind placebo-con-
trolled trials, nonanemic iron-depleted women
receiving iron supplements showed a progressive
and significant decrease in sTfR and sTfR/ferritin
ratio [74,75]. Similar results were obtained in ado-
lescent boys in whom a 50-day course of iron
supplementation resulted in a significant, albeit
small, drop of sTfR levels [10]. Intravenous iron
therapy for severe anemia in systemic-onset juvenile
chronic arthritis resulted in a correction of anemia
together with a considerable drop in sTfR values
[19,76].
In another major study, apparently healthy non-
anemic adults were supplemented with oral iron for
3 months to evaluate its effect on various parameters of
iron status [77]. Iron supplementation did not induce
any significant change in iron parameters in men, but
reduced sTfR levels and increased ferritin levels in a
significant proportion of women. Changes in sTfR
occurred mainly in subjects with elevated values
before supplementation. Of the 65 subjects, 25 were
retrospectively judged to have had storage iron deple-
Fig. 3. MeanF 1 S.D. sTfR levels in groups of patients with
abnormal iron status, including nonanemic iron deficiency (ID), iron
deficiency anemia (IDA) and idiopathic hemochromatosis (IH). The
gray zone represents the reference interval in normal subjects.
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tion or depletion of the functional compartment. This
indicates that iron-deficient erythropoiesis may occur
in subjects thought to be iron replete on the basis of
ferritin values. The normal values of sTfR, ferritin and
sTfR–ferritin index should therefore be those obtained
in these healthy adults after 3 months of iron supple-
mentation had corrected subclinical iron depletion. In
particular, the upper limit of normal sTfR values
should be lowered to allow detection of incipient
iron-deficient erythropoiesis. Iron stores may not need
to be exhausted to have clinically relevant storage
depletion. Subtle changes in functional iron supply
have been illustrated in a study of obese patients
undergoing a very-low-energy all-protein diet [78].
The serum iron and transferrin saturation fell sharply
within 1 week and this was followed by moderate
increases in sTfR correlating inversely with prior
changes in serum iron. These results indicate that
depressed serum iron, probably related to altered iron
release by reticuloendothelial cells, induces functional
tissue iron deficiency too short in duration to produce
alterations in red blood cell indices. However, sTfR
levels remained in the normal range and iron-deficient
erythropoiesis could not have been detected if serial
samples had not been obtained.
4.2. Soluble TfR and inflammation
As sTfR levels are not increased in patients with
inflammation of unknown origin [79], the anemia of
chronic disorders [80,81], HIV infection [82], acute
infection [81,83] or in chronic liver disorders [81],
they may help distinguish these clinical problems
from iron deficiency (Table 2) [61,81,84–86]. Indeed,
sTfR levels may not be increased despite evidence of
functional iron deficiency as evidenced by elevated
zinc protoporphyrin [72]. Furthermore, sTfR levels
may decrease temporarily during acute inflammation
[7]. Blunted Epo production and suppression of eryth-
ropoiesis by cytokines may be the reasons for the
absence of elevation of sTfR in the anemia of inflam-
mation.
On the other hand, patients with the anemia of
chronic disorders may also have concomitant true iron
deficiency and then show sTfR levels similarly ele-
vated as in pure iron deficiency anemia (Table 2), even
if these studies were not always based on a gold
standard such as marrow iron determination [19,61,
76,87–91]. Values of sTfR decrease after adequate iron
supplementation, independently of marrow iron stores,
indicating that they are good indicators of functional
iron deficiency [90]. Contrarily to serum ferritin, sTfR
may thus prove to be a diagnostic test of iron deficiency
in patients with inflammation. However, in some
studies, sTfR levels could not distinguish accurately
among patients with rheumatoid arthritis [92,93],
inflammatory bowel disease [94] or other inflammatory
disorders [95], those with or without iron deficiency. In
addition, several studies have observed higher sTfR
levels in iron-replete rheumatoid arthritis patients com-
pared to normal subjects, even if they remain lower
than in iron deficiency anemia [92,96–98]. Similarly,
sTfR levels were increased in a large group of patients
with systemic lupus erythematosus but no information
is available on their iron status [99]. Levels were
inversely related to Hb values, suggesting that they
originated from stimulated erythropoiesis. Alterna-
tively, this may indicate functional iron deficiency.
Indeed, sTfR levels were elevated in cystic fibrosis
patients with other signs of functional iron deficiency
and were correlated with the degree of inflammation
[100]. Therefore, the cutoff point for the diagnosis of
depleted iron stores in a patient with inflammation
could be higher than the upper limit of normal values
[87].
In addition, serum ferritin, with cutoff points rang-
ing from 30 to 100 Ag/l, in some studies offered an
equivalent or even better prediction of bone marrow
iron content [88,93,97,101–103] or of Hb response to
iron supplementation [86,104]. However, the com-
bined use of sTfR and ferritin or the use of TfR/ferritin
or TfR/log ferritin ratios may increase the efficacy of
sTfR in identifying iron deficiency in patients with
chronic inflammation [61,87,88,94,103]. In particular,
the log (sTfR/ferritin) ratio may prove superior to the
sTfR/log ferritin index [68].
Table 2
Differential diagnosis between iron deficiency anemia (IDA),
anemia of chronic disorder (ACD) and the combination of
ACD+ IDA
Hb Serum iron Ferritin sTfR sTfR/ferritin
IDA # # # z zz
ACD # # N–z N N
ACD+ IDA # # z z z
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5. Soluble TfR: a marker of iron status and/or
erythropoiesis?
Within the iron-replete range, sTfR correlates with
Hb but not with markers of iron status such as trans-
ferrin saturation and ferritin [8,67,105–107]. An
inverse correlation between sTfR and ferritin may
even represent an association between erythropoietic
activity and iron utilization for erythropoiesis rather
than an effect of iron stores on TfR expression [107].
Soluble TfR is therefore only a marker of erythropoi-
esis when iron stores are adequate and available and
additionally becomes a marker of iron status only
when tissue iron deficiency (with or without adequate
iron stores) occurs. While sTfR has proved to be a
reliable marker of tissue iron deficiency, the interpre-
tation of an individual value may be tricky in a patient
in whom both changes in erythropoietic activity and
iron status may occur simultaneously. In unselected
populations of patients with a variety of diagnoses, the
specificity and positive predictive value of an elevated
sTfR level for the diagnosis of iron deficiency is low
because many patients have other reasons (predom-
inantly increased erythropoiesis) for it [65]. Combin-
ing sTfR and ferritin measurements may increase
specificity but not sensitivity for the diagnosis of iron
deficiency in such a population [108].
In patients with rheumatoid arthritis or other forms
of anemia of chronic disorders, sTfR levels may well
remain within the normal range even when iron stores
are depleted [93] because cytokines or other factors
also suppress erythropoiesis directly or through inhib-
ition of Epo production. On the other hand, levels may
be elevated even when iron stores are adequate [96]
because marrow erythropoietic activity may be
increased. Therefore, the relationship between iron
status and sTfR levels in patients with inflammation
depends on the severity of inflammation, the degree of
anemia, the adequacy of Epo production and the effect
of cytokines on marrow activity.
In other situations as well, it may be difficult to
distinguish the respective influence of erythropoiesis
and iron deficiency on sTfR levels. Patients with
chronic liver disease may have elevated sTfR levels
when they experience either iron deficiency or stimu-
lated erythropoiesis in response to hemolysis or hem-
orrhage [109]. Renal failure patients have low sTfR
levels as a result of erythroid hypoplasia [12,42] and
iron deficiency is then associated with a relative
elevation of sTfR levels that nevertheless remain
within the normal range [33,110]. Active malaria is
associated with changes in erythropoietic activity
brought about by hemolysis (which would tend to
increase sTfR levels) as well as inflammation (which
would rather decrease sTfR levels). The predominant
effect was shown to be suppression of erythropoiesis
by inflammation in active malaria, resulting in
decreased sTfR levels [111–113], and appropriate
marrow response to mild anemia in asymptomatic
infection, with elevated sTfR levels [114,115]. Thus
the diagnostic value of sTfR levels for iron deficiency
may be impaired in individuals living in highly
endemic areas for malaria [116,117].
The interpretation of sTfR values could be even
more difficult in patients treated with rHuEpo, where
erythropoietic response is often associated with func-
tional iron deficiency. If sTfR was mostly a marker of
functional iron deficiency induced by rHuEpo, it
should increase more consistently in nonresponders
(primary cause of failure is functional iron deficiency)
than in responders: in fact the reverse is true [33,118].
In addition, sTfR increments correlate well with later
hematocrit increases [32], whereas levels are not
different in patients with low or high ferritin [119]
and correction of iron deficiency with oral iron is
associated with little changes [118,120]. Furthermore,
the elevation of sTfR in response to rHuEpo is larger
in iron overloaded rats than in normal animals who
develop functional iron deficiency [121]. Therefore
sTfR remains predominantly a marker of erythroid
response to rHuEpo.
Another situation where changes in iron status and
erythropoiesis interact is pregnancy. Actually, sTfR
levels are decreased in the first two trimesters, normal-
ize in the first part of the 3rd trimester, and are slightly
increased in late pregnancy and the early postpartum
[122–125]. These changes in erythropoietic activity
are still well apparent after carefully excluding iron-
deficient women [126], parallel those in Epo produc-
tion [122] and reticulocytes [126], and thus explain
known alterations in the red cell mass throughout
pregnancy. On the other hand, some studies have
found that depletion of iron stores also produced a
moderate elevation of sTfR over levels observed in
non-iron-deficient pregnancies [122,127], particularly
at time of labor [128]. Others have found that among
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anemic as well as among nonanemic pregnancies,
sTfR values are not influenced by iron stores
[82,124]. Thus, elevated sTfR levels in late third
trimester may help identify iron-deficient erythropoi-
esis with satisfactory specificity but low sensitivity,
but reduced erythropoiesis limits the possibility of
detecting iron deficiency in the rest of pregnancy
[123,128,129].
6. Soluble TfR as a tumor marker
Increased expression of transferrin receptors has
been documented on the surface of malignant tumors
as compared to their normal counterparts. A number
of studies have evaluated sTfR levels in erythroid
(Fig. 4) as well as nonerythroid malignancies (Fig. 5).
Soluble TfR levels are elevated in patients with
myelofibrosis and myeloproliferative disorders, but
are essentially within the normal range in chronic
myelogenous leukemia or essential thrombocythemia,
which is in keeping with our understanding of eryth-
ropoiesis in these disorders [12,130]. Patients with
MDS may have decreased, normal or elevated levels,
reflecting the various patterns of erythropoiesis
encountered in these disorders [12,15,131,132]. In
patients with polycythemia vera, sTfR levels may be
considerably elevated [12], although this may be
partly because of phlebotomy-induced iron depletion.
Soluble TfR levels are normal or decreased in patients
with solid tumors [12,16,133], with the possible
exception of those with hepatocellular carcinoma
[134]. Levels in acute leukemia have been found to
be decreased at diagnosis and during chemotherapy
[12,16,130,135]. Patients with many lymphoid malig-
nancies, including hairy cell leukemia and multiple
myeloma, have been found to have normal sTfR
values, but this represents relative marrow failure for
the degree of anemia [12,18,130,135]. However, lev-
els may be considerably elevated in chronic lympho-
cytic leukemia [17,130]. The significance of this is
unclear. On the one hand, sTfR levels are not
increased beyond what is expected if the bone marrow
is capable of responding adequately to an appropriate
Epo stimulation for the degree of anemia [17]. This
would indicate that the pathogenesis of anemia in
CLL is in large part related to hemolysis and/or
hypersplenism. On the other hand, sTfR correlated
strongly with the levels of other soluble receptors,
including CD23, a marker of the tumor burden.
Appropriate sTfR levels for the degree of anemia
could in fact result from an inadequately small amount
of erythropoietic cell-derived sTfR with an exagger-
ated release by malignant lymphocytes. In patients
with high-grade non-Hodgkin’s lymphoma, elevated
sTfR levels have been observed, which correlate with
the tumor burden and clinical stage and normalize in
patients responding to chemotherapy [135,136]. In
Fig. 4. MeanF 1 S.D. sTfR levels in groups of patients with
malignancies involving the erythron, including agnogenic myeloid
metaplasia (AMM), myelodysplastic syndrome (MDS) and poly-
cythemia vera (PV). The gray zone represents the reference interval
in normal subjects.
Fig. 5. MeanF 1 S.D. sTfR levels in groups of patients with
nonerythroid malignancies, including myeloproliferative disorders
(MPD), acute lymphoblastic leukemia (ALL), chronic lymphocytic
leukemia (CLL), multiple myeloma (MM), lung cancer (Lung) and
miscellaneous solid tumors (Solid). The gray zone represents the
reference interval in normal subjects.
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conclusion, sTfR derived from tumor cells do not
contribute significantly to overall sTfR levels, with
the possible exception of non-Hodgkin’s lymphoma,
CLL and hepatocellular carcinoma.
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